GAIN THERAPEUTICS INC (GANX)
US36269B1052 - Common Stock
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 160K 433.33% | 140K -12.50% | 55.18K -60.59% | -100.00% | 51K | -100.00% | 22.387M | 94.119M 320.42% | 157.57M 67.42% | |||
| EBITDA YoY % growth | -13.81M -297.98% | -17.72M -28.31% | -22.17M -25.11% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -13.83M -297.41% | -17.78M -28.56% | -22.253M -25.16% | -22.7M -2.01% | -25.662M -13.05% | -33.304M -29.78% | -39.881M -19.75% | -46.083M -15.55% | -5.094M 88.95% | 105.35M 2,168.17% | 187.18M 77.67% | |
| Operating Margin | -8,643.75% | -12,700.00% | -40,328.25% | N/A | -50,318.00% | N/A | N/A | N/A | -22.75% | 111.93% | 118.79% | |
| EPS YoY % growth | -1.51 | -1.48 1.99% | -1.78 -20.27% | -1.00 43.65% | -0.83 17.22% | -1.23 -48.65% | -1.76 -42.98% | -2.18 -23.70% | -0.13 93.93% | 1.79 1,446.15% | N/A |
All data in USD
| Q4 / 24 | Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.20 45.46% | -0.19 11.91% | -0.20 52.64% | -0.19 -11.00% | -0.18 6.49% |
| Revenue Q2Q % growth | 33.997K | 51K | 51K | 51K | 51K 50.02% |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -5M -13.46% | N/A | N/A | N/A | N/A |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | -0.17 54.05% | -0.22 | 0.05 | 22.48% |
| Q2 2024 Q2Q % growth | -0.42 32.26% | -0.20 | -0.22 | -105.88% |
| Q1 2024 Q2Q % growth | -0.22 48.84% | -0.30 | 0.08 | 26.26% |
| Q4 2023 Q2Q % growth | -0.36 7.69% | -0.33 | -0.03 | -9.44% |
| Q3 2023 Q2Q % growth | -0.37 2.63% | -0.45 | 0.08 | 18.67% |
| Q2 2023 Q2Q % growth | -0.62 -44.19% | -0.31 | -0.31 | -97.67% |
| Q1 2023 Q2Q % growth | -0.43 -53.57% | -0.40 | -0.03 | -7.18% |
| Q4 2022 Q2Q % growth | -0.39 -21.88% | -0.39 | 0.00 | -1.29% |
| Q3 2022 Q2Q % growth | -0.38 2.56% | -0.47 | 0.09 | 19.01% |
| Q2 2022 Q2Q % growth | -0.43 -43.33% | -0.32 | -0.11 | -34.54% |
| Q1 2022 Q2Q % growth | -0.28 44.00% | -0.37 | 0.09 | 25.30% |
| Q4 2021 Q2Q % growth | -0.32 | -0.50 | 0.18 | 35.54% |
| Q3 2021 Q2Q % growth | -0.39 | -0.36 | -0.03 | -7.20% |
| Q2 2021 Q2Q % growth | -0.30 | -0.31 | 0.01 | 3.57% |
| Q1 2021 Q2Q % growth | -0.50 | -0.22 | -0.28 | -128.00% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2024 Q2Q % growth | 408K | -408K | -100.00% | |
| Q1 2024 Q2Q % growth | -100.00% | 30.6K | -30.6K | -100.00% |
| Q4 2023 Q2Q % growth | 331.5K | -331.5K | -100.00% | |
| Q3 2023 Q2Q % growth | 280.296K | -280.296K | -100.00% | |
| Q2 2023 Q2Q % growth | -100.00% | 1.034M | -1.034M | -100.00% |
| Q1 2023 Q2Q % growth | 55K 10.00% | 55K | % | |
| Q4 2022 Q2Q % growth | -100.00% | 12.75K | -12.75K | -100.00% |
| Q3 2022 Q2Q % growth | -100.00% | 58.905K | -58.905K | -100.00% |
| Q2 2022 Q2Q % growth | 100K 11.11% | 27.877K | 72.123K | 258.72% |
| Q1 2022 Q2Q % growth | 50K 400.00% | 39.78K | 10.22K | 25.69% |
| Q4 2021 Q2Q % growth | 40K | 52.53K | -12.53K | -23.85% |
| Q3 2021 Q2Q % growth | 30K | 13.597K | 16.403K | 120.64% |
| Q2 2021 Q2Q % growth | 90K 800.00% | 90K | % | |
| Q1 2021 Q2Q % growth | 10K | 10K | % |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 3.75% | 25% | 6.57% | 6.57% |
| Revenue | 0% | -75.31% | -100% | -100% |